title: Melanoma in the elderly patient: relevance of the aging immune system.
abstract: The rapidly expanding segment of the aging population with its rising incidence of cutaneous melanoma will present major challenges in therapeutic management. Immune strategies will be important in designing effective treatment of melanoma because it is a highly immunogenic tumor. Aging, however, is associated with dysregulation of the immune system and is likely to affect the success of melanoma treatment in the elderly population. This population represents an ideal in vivo model to study the effects of the aging immune system on the natural history of melanoma in the elderly. We review the epidemiology, histopathologic features, and treatment outcomes of elderly melanoma patients with reference to their immune function. Various components of the normal immune system are described, and the immune response to melanoma is recapitulated. Particular emphasis is placed on the growing understanding of the innate, adaptive, and regulatory arms of the aging immune system.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, The Carole and Ray Neag Comprehensive Cancer Institute, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA. uhegde@uchc.edu
authors.forename: Upendra P
authors.initials: UP
authors.lastname: Hegde
authors.forename: Nitya
authors.initials: N
authors.lastname: Chakraborty
authors.forename: Philip
authors.initials: P
authors.lastname: Kerr
authors.forename: Jane M
authors.initials: JM
authors.lastname: Grant-Kels
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology* / Q000502:physiology; D003131:Combined Modality Therapy; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D007113:Immunity, Innate / Q000502:physiology; D016867:Immunocompromised Host; D015994:Incidence; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D016019:Survival Analysis